Ozempic vs Wegovy: Same Molecule, Different Indications

Ozempic and Wegovy are both semaglutide—the active pharmaceutical ingredient is identical. The difference lies in the approved indication, approved dosing regimen, brand name, and labelling. Ozempic is approved and marketed for type 2 diabetes mellitus, with an approved weekly dose range of 0.5–1.4 mg. Wegovy is approved and marketed for chronic weight management, with an approved weekly dose range of 0.25–2.4 mg. Both are administered by subcutaneous injection once weekly; both are manufactured by Novo Nordisk.

From a pharmacological perspective, there is no chemical or biological difference between Ozempic semaglutide and Wegovy semaglutide—the semaglutide molecule is identical. The regulatory distinction reflects different clinical trial programs (SUSTAIN for diabetes; STEP for weight management) and different approved therapeutic contexts. This distinction is important for prescribing and insurance coverage, but not for understanding the drug's mechanism or pharmacology.

Ozempic (semaglutide for type 2 diabetes) is indicated for improving glycaemic control in adults with type 2 diabetes. The approved dosing is 0.5 mg weekly, escalating to 1.0 mg then 1.4 mg based on clinical response and tolerability. Most diabetic patients achieve target HbA1c with the 1.0 mg dose; the 1.4 mg dose provides additional glycaemic benefit for some patients. The dosing regimen reflects the SUSTAIN trial design, where doses of 0.5–1.4 mg were evaluated.

Wegovy (semaglutide for chronic weight management) is indicated for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with weight-related comorbidities. The approved dosing escalates from 0.25 mg (maintenance dose 0.5 mg), then 1.0 mg, 1.7 mg, and finally 2.4 mg based on tolerability and weight loss response. The 2.4 mg dose is the target maintenance dose for maximal weight loss. This higher dosing reflects the STEP trial design, where semaglutide 2.4 mg weekly was the highest tested dose and demonstrated maximal weight loss.

Both Ozempic and Wegovy activate the GLP-1 receptor identically—the mechanism is not different between the brand names. In diabetes, GLP-1 receptor activation promotes glucose-dependent insulin secretion and suppresses glucagon, lowering fasting and postprandial glucose. In weight management, GLP-1 receptor activation suppresses appetite in the hypothalamus, reduces meal size, and modestly increases energy expenditure. The biological mechanism is the same; the clinical context (diabetes vs. obesity treatment) differs.

An important implication: a patient on Ozempic (diabetes) experiencing weight loss is benefiting from the same mechanism as a patient on Wegovy experiencing weight loss. The weight loss is not a 'side effect' of diabetes treatment but rather an on-target effect of GLP-1 agonism. Conversely, a patient on Wegovy (weight management) typically experiences improved glucose control and metabolic parameters. The pharmacology is holistic—GLP-1 agonism addresses multiple metabolic and homeostatic processes simultaneously.

Regulatory and prescribing differences are substantial. Ozempic is approved and indicated for type 2 diabetes; prescribing it for weight management in non-diabetic obese patients is 'off-label' use (not formally approved, though clinically possible). Conversely, Wegovy is approved for weight management; using it in diabetic patients is also off-label. From a regulatory perspective, each product should be used within its approved indication.

Access and cost differences are important: Ozempic (diabetes) is often covered by health insurance (in Australia, PBS-subsidised) due to diabetes being a major public health condition. Wegovy (weight management) is more often a private prescription with higher out-of-pocket costs in many countries. This creates a practical distinction: a diabetic patient can access semaglutide through their diabetes treatment pathway (Ozempic) at lower cost; a non-diabetic obese patient wanting semaglutide must use Wegovy and typically bears higher costs. Some patients and prescribers have attempted to circumvent this by obtaining 'off-label' Ozempic prescriptions, though this exists in a regulatory grey area.

Ozempic's evidence base comes from the SUSTAIN program (13 trials, >13,000 diabetes participants), demonstrating HbA1c reductions of 1.0–1.8 percentage points and cardiovascular benefit in SUSTAIN-6. Wegovy's evidence base comes from the STEP program (4 trials, >4,500 weight management participants), demonstrating weight loss of 10–15% on average and cardiovascular benefit in SELECT. The trial designs were distinct—SUSTAIN focused on glycaemic control, while STEP focused on weight loss—reflecting the different regulatory pathways and indications.

An important point: the STEP trials included semaglutide 2.4 mg weekly (Wegovy dose), while the SUSTAIN trials used lower doses (0.5–1.4 mg, Ozempic doses). This dosing difference explains the greater weight loss in STEP (10–15%) compared to SUSTAIN (2–4 kg). If SUSTAIN had used the 2.4 mg dose, weight loss would likely have been considerably greater. This distinction illustrates that the indications are partly driven by dosing/trial design rather than fundamental pharmacological differences.